Clinical Trial Update: Daclizumab Versus Thymoglobulin in Renal Transplant Recipients With High Immunological Risk [Phase 3]

View source ↗

Summary

A Phase 3 randomized trial comparing daclizumab to thymoglobulin in high-immunological-risk renal transplant recipients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Transplantation

Drugs mentioned

• Daclizumab (daclizumab)
• Thymoglobulin (rabbit anti-thymocyte globulin)

Snippet

Sponsor: University Hospital, Lille | Conditions: Renal Transplantation | Phase 3 | Status: COMPLETED